Piper sees GLP-1s increasing demand for knee/hip surgeries near-term (NYSE:NVO)
Mohammed Haneefa Nizamudeen/iStock via Getty Images Piper Sandler said it expects upcoming results from a Novo Nordisk (NVO) study of its weight-loss drug semaglutide in the treatment of osteoarthritis to be “mediocre” and demand for…
